首页 > 最新文献

MedComm - Future medicine最新文献

英文 中文
Deep learning methods for protein structure prediction 用于蛋白质结构预测的深度学习方法
Pub Date : 2024-09-23 DOI: 10.1002/mef2.96
Yiming Qin, Zihan Chen, Ye Peng, Ying Xiao, Tian Zhong, Xi Yu

Protein structure prediction (PSP) has been a prominent topic in bioinformatics and computational biology, aiming to predict protein function and structure from sequence data. The three-dimensional conformation of proteins is pivotal for their intricate biological roles. With the advancement of computational capabilities and the adoption of deep learning (DL) technologies (especially Transformer network architectures), the PSP field has ushered in a brand-new era of “neuralization.” Here, we focus on reviewing the evolution of PSP from traditional to modern deep learning-based approaches and the characteristics of various structural prediction methods. This emphasizes the advantages of deep learning-based hybrid prediction methods over traditional approaches. This study also provides a summary analysis of widely used bioinformatics databases and the latest structure prediction models. It discusses deep learning networks and algorithmic optimization for model training, validation, and evaluation. In addition, a summary discussion of the major advances in deep learning-based protein structure prediction is presented. The update of AlphaFold 3 further extends the boundaries of prediction models, especially in protein-small molecule structure prediction. This marks a key shift toward a holistic approach in biomolecular structure elucidation, aiming at solving almost all sequence-to-structure puzzles in various biological phenomena.

蛋白质结构预测(PSP)一直是生物信息学和计算生物学的一个重要课题,其目的是从序列数据中预测蛋白质的功能和结构。蛋白质的三维构象对其复杂的生物学作用至关重要。随着计算能力的提升和深度学习(DL)技术(尤其是 Transformer 网络架构)的采用,PSP 领域迎来了一个全新的 "神经化 "时代。在此,我们将重点回顾 PSP 从传统方法到基于深度学习的现代方法的演变过程,以及各种结构预测方法的特点。这强调了基于深度学习的混合预测方法相对于传统方法的优势。本研究还对广泛使用的生物信息学数据库和最新的结构预测模型进行了总结分析。研究还讨论了深度学习网络以及用于模型训练、验证和评估的算法优化。此外,还总结讨论了基于深度学习的蛋白质结构预测的主要进展。AlphaFold 3 的更新进一步扩展了预测模型的边界,尤其是在蛋白质-小分子结构预测方面。这标志着生物分子结构阐释向整体方法的关键转变,旨在解决各种生物现象中几乎所有序列到结构的难题。
{"title":"Deep learning methods for protein structure prediction","authors":"Yiming Qin,&nbsp;Zihan Chen,&nbsp;Ye Peng,&nbsp;Ying Xiao,&nbsp;Tian Zhong,&nbsp;Xi Yu","doi":"10.1002/mef2.96","DOIUrl":"https://doi.org/10.1002/mef2.96","url":null,"abstract":"<p>Protein structure prediction (PSP) has been a prominent topic in bioinformatics and computational biology, aiming to predict protein function and structure from sequence data. The three-dimensional conformation of proteins is pivotal for their intricate biological roles. With the advancement of computational capabilities and the adoption of deep learning (DL) technologies (especially Transformer network architectures), the PSP field has ushered in a brand-new era of “neuralization.” Here, we focus on reviewing the evolution of PSP from traditional to modern deep learning-based approaches and the characteristics of various structural prediction methods. This emphasizes the advantages of deep learning-based hybrid prediction methods over traditional approaches. This study also provides a summary analysis of widely used bioinformatics databases and the latest structure prediction models. It discusses deep learning networks and algorithmic optimization for model training, validation, and evaluation. In addition, a summary discussion of the major advances in deep learning-based protein structure prediction is presented. The update of AlphaFold 3 further extends the boundaries of prediction models, especially in protein-small molecule structure prediction. This marks a key shift toward a holistic approach in biomolecular structure elucidation, aiming at solving almost all sequence-to-structure puzzles in various biological phenomena.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.96","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142316636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAPability-01: Success of anti-PD-1, HDAC inhibitor, and anti-VEGF combination in colorectal cancer CAPability-01:抗 PD-1、HDAC 抑制剂和抗血管内皮生长因子联合疗法在结直肠癌中的成功应用
Pub Date : 2024-09-18 DOI: 10.1002/mef2.97
Yujie Tan, Yunfang Yu
<p>The CAPability-01 trial, led by Feng Wang et al.,<span><sup>1</sup></span> was published in <i>Nature Medicine</i> on March 04, 2024. This study highlighted that a triplet regimen of the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab significantly improved the progression-free survival (PFS) and response in microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC).</p><p>CAPability-01 trial is a randomized, open-label, multicenter, Phase 2 clinical trial, that evaluated the efficacy of a triplet therapy (sintilimab, chidamide, and bevacizumab) versus a doublet (sintilimab with chidamide) in patients with unresectable, chemotherapy-refractory, locally advanced or metastatic MSS/pMMR CRC. Forty-eight patients were enrolled and randomly assigned in a 1:1 ratio to receive the triplet or doublet treatment.</p><p>The study found that the triplet regimen outperformed the doublet regimen in most key endpoints. More than 50% of the patients presented with liver metastases or lung metastases at baseline. Treatment histories were diverse, with almost half of the patients, particularly in the doublet group, receiving third-line or later treatment. The triplet treatment group exhibited a significantly higher PFS rate and improved overall response rate (ORR) and disease control rate (DCR) compared to the doublet group, with 44% achieving partial response and 28% maintaining stable disease. Subgroup analysis revealed that patients with liver metastases benefited more from the triplet treatment, showing significantly notably better outcomes in PFS (7.3 months vs. 1.4 months, <i>p</i> = 0.001), ORR (50.0% vs. 8.3%), and DCR (71.4% vs. 8.3%) compared with those on the doublet regimen. In this study, the incidence rates of treatment-related side effects (TEAEs) occurred in 60.0% of patients in the triplet group and 30.4% in the doublet therapy. Grade 3 or higher adverse events included thrombocytopenia, reported in 16.0% of patients receiving triplet therapy compared to 8.7% in the doublet group, and neutropenia, which was reported at 28.0% for the triplet therapy and not at all for the doublet. The triplet regimen appeared promising for patients with MSS/pMMR unresectable advanced or metastatic CRC, providing longer progression-free survival and manageable toxicity.</p><p>Despite the advancements in chemotherapy and target therapy, the prognosis of most patients with unresectable locally advanced or metastatic CRC remains poor. Several studies are currently evaluating the effectiveness of immune checkpoint inhibitors (ICIs), antiangiogenesis therapy, and HDAC inhibitors in treating microsatellite instability-high/deficient mismatch repair phenotypes (MSI-H/dMMR) CRC (Table 1). ICIs, like PD-1 antibodies and CTLA-4 antibodies, have demonstrated impressive clinical benefit
3.在令人鼓舞的临床前研究结果的推动下,已经开展了各种临床试验来评估这种组合的有效性。例如,REGONIVO 研究评估了 nivolumab 和瑞戈非尼联合治疗 MSS/pMMR 晚期 CRC 患者的效果,结果显示 mPFS 为 7.9 个月,1 年的 PFS 率为 41.8%,反映了积极的结果。例如,I/Ib 期临床试验 NCT03712943 考察了瑞戈非尼联合 nivolumab 治疗 pMMR mCRC 的安全性和有效性,10% 的患者获得 PR,53% 的患者维持 SD,DCR 为 63%。mPFS和OS分别为4.3个月和11.1个月。相比之下,另一项名为 NCT04126733 的试验报告显示,疾病控制率为 39%,mPFS 和 OS 分别为 1.8 个月和 11.9 个月。HDACi通过调节PD-L1的表达以及免疫细胞活化、分化和效应功能的表观遗传学,有望促进抗肿瘤免疫微环境的形成。虽然HDACi与PD-1/PD-L1抑制剂联合治疗淋巴瘤取得了令人鼓舞的疗效,但它们对实体瘤(如非小细胞肺癌和乳腺癌)的疗效并不明显,总体反应率在6.7%到10%之间。HDACi、抗血管内皮生长因子和抗PD-1疗法的联合治疗,即所谓的三联疗法,在治疗MSS/pMMR晚期CRC,尤其是肝转移的CRC方面显示出更强的疗效。临床前研究和临床试验都证实了这种疗效的提高。例如,在一项使用瑞戈非尼和 nivolumab 治疗 pMMR mCRC 的 2 期研究中,与没有肝转移的患者相比,有肝转移的患者 ORR 更低(4% 对 25%),PFS 更短(中位:2.3 个月对 8.9 个月),OS 更短(中位:9.7 个月对未达到)。此外,在 REGONIVO 研究中,所有入组 CRC 患者的 ORR 为 36%,但肝转移患者的 ORR 仅为 15.4%。同样,REGOTORI 研究发现,与无肝转移的患者相比,有肝转移的患者的反应率较低(8.7% 对 30.0%)。5 然而,CAPability-01 试验表明,无论是否有肝转移,三联疗法在 mCRC 中都具有卓越的疗效。因此,还需要进一步的研究来证实这些结果,并深入了解其潜在机制。在这些研究结果的基础上,一项多中心、随机、III 期试验--CAPability-02 已经启动,研究对象是一线治疗(包括以奥沙利铂为基础的化疗)失败的 MSS 型 CRC 患者。CAPability-01试验发现,在化疗难治的MSS/pMMR型CRC患者中,使用辛替利马单抗、奇达霉素和贝伐珠单抗的三联疗法能显著改善化疗双联疗法的PFS、ORR和DCR。三联疗法还创造了更活跃的免疫肿瘤微环境,增强了CD8 + T细胞浸润。研究结果表明,这种联合疗法可能是治疗晚期 CRC 的一种很有前景的方法,尤其是对于肝转移患者,因为传统上肝转移患者的治疗效果较差:构思(牵头);项目管理(相同);撰写-初稿(相同);撰写-审阅和编辑(相同)。余云芳:构思(等同);经费获取(等同);项目管理(等同);指导(主要)。两位作者均已阅读并批准最终稿件。作者声明无利益冲突。
{"title":"CAPability-01: Success of anti-PD-1, HDAC inhibitor, and anti-VEGF combination in colorectal cancer","authors":"Yujie Tan,&nbsp;Yunfang Yu","doi":"10.1002/mef2.97","DOIUrl":"https://doi.org/10.1002/mef2.97","url":null,"abstract":"&lt;p&gt;The CAPability-01 trial, led by Feng Wang et al.,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; was published in &lt;i&gt;Nature Medicine&lt;/i&gt; on March 04, 2024. This study highlighted that a triplet regimen of the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab significantly improved the progression-free survival (PFS) and response in microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC).&lt;/p&gt;&lt;p&gt;CAPability-01 trial is a randomized, open-label, multicenter, Phase 2 clinical trial, that evaluated the efficacy of a triplet therapy (sintilimab, chidamide, and bevacizumab) versus a doublet (sintilimab with chidamide) in patients with unresectable, chemotherapy-refractory, locally advanced or metastatic MSS/pMMR CRC. Forty-eight patients were enrolled and randomly assigned in a 1:1 ratio to receive the triplet or doublet treatment.&lt;/p&gt;&lt;p&gt;The study found that the triplet regimen outperformed the doublet regimen in most key endpoints. More than 50% of the patients presented with liver metastases or lung metastases at baseline. Treatment histories were diverse, with almost half of the patients, particularly in the doublet group, receiving third-line or later treatment. The triplet treatment group exhibited a significantly higher PFS rate and improved overall response rate (ORR) and disease control rate (DCR) compared to the doublet group, with 44% achieving partial response and 28% maintaining stable disease. Subgroup analysis revealed that patients with liver metastases benefited more from the triplet treatment, showing significantly notably better outcomes in PFS (7.3 months vs. 1.4 months, &lt;i&gt;p&lt;/i&gt; = 0.001), ORR (50.0% vs. 8.3%), and DCR (71.4% vs. 8.3%) compared with those on the doublet regimen. In this study, the incidence rates of treatment-related side effects (TEAEs) occurred in 60.0% of patients in the triplet group and 30.4% in the doublet therapy. Grade 3 or higher adverse events included thrombocytopenia, reported in 16.0% of patients receiving triplet therapy compared to 8.7% in the doublet group, and neutropenia, which was reported at 28.0% for the triplet therapy and not at all for the doublet. The triplet regimen appeared promising for patients with MSS/pMMR unresectable advanced or metastatic CRC, providing longer progression-free survival and manageable toxicity.&lt;/p&gt;&lt;p&gt;Despite the advancements in chemotherapy and target therapy, the prognosis of most patients with unresectable locally advanced or metastatic CRC remains poor. Several studies are currently evaluating the effectiveness of immune checkpoint inhibitors (ICIs), antiangiogenesis therapy, and HDAC inhibitors in treating microsatellite instability-high/deficient mismatch repair phenotypes (MSI-H/dMMR) CRC (Table 1). ICIs, like PD-1 antibodies and CTLA-4 antibodies, have demonstrated impressive clinical benefit","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.97","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corneal epithelial ingrowth after small incision lenticule extraction surgery: Insights from a case series and mechanistic studies 小切口皮瓣摘除手术后的角膜上皮生长:系列病例和机理研究的启示
Pub Date : 2024-09-18 DOI: 10.1002/mef2.99
Miao Zhang, Ieng Chong, Xiaoniao Chen, Juan Yang, Linling Cheng, Zonghui Yan

Corneal epithelial ingrowth (EI) is a rare but significant complication following Small Incision Lenticule Extraction (SMILE) surgery. During the procedure, the opaque bubble layer (OBL) formation may create microchannels that disrupt Bowman's layer, providing a pathway for epithelial cells to migrate into the corneal stroma. In this study, we investigated the mechanisms behind EI development and proposed preventive strategies. We analyzed four cases of EI post-SMILE surgery, utilizing anterior segment optical coherence tomography (AS-OCT) and corneal tomography for diagnosis. Preventive measures, including careful anesthetic application and precise suction cone positioning, were employed to minimize OBL formation. Here, we show that subflap debris removal surgery led to significant clinical improvement, with no EI recurrence observed. Our findings suggest that the microchannels created by OBL during surgery may play a crucial role in EI development, challenging previous assumptions that EI is primarily due to trauma at the flap edges. This underscores the importance of precise surgical technique and effective postoperative management. Further research, including clinical studies and advanced imaging, is needed to confirm this proposed mechanism and improve outcomes in refractive surgery. The study highlights the necessity for ongoing advancements in surgical protocols and technology to prevent and manage EI effectively.

角膜上皮增生(EI)是小切口角膜透镜摘除术(SMILE)后的一种罕见但严重的并发症。在手术过程中,不透明气泡层(OBL)的形成可能会产生微通道,破坏鲍曼层,为上皮细胞移入角膜基质提供途径。在本研究中,我们研究了 EI 的形成机制,并提出了预防策略。我们利用眼前节光学相干断层扫描(AS-OCT)和角膜断层扫描进行诊断,分析了四例SMILE手术后EI病例。我们采取了预防措施,包括谨慎使用麻醉剂和精确定位吸引锥,以尽量减少 OBL 的形成。在此,我们展示了角膜瓣下碎屑清除手术带来的显著临床改善,并且没有观察到 EI 复发。我们的研究结果表明,OBL 在手术过程中形成的微通道可能在 EI 的形成过程中起着至关重要的作用,这对之前认为 EI 主要是由皮瓣边缘的创伤造成的假设提出了质疑。这强调了精确的手术技术和有效的术后管理的重要性。需要进一步的研究,包括临床研究和先进的成像技术,来证实这一机制并改善屈光手术的效果。这项研究强调了不断改进手术方案和技术以有效预防和管理 EI 的必要性。
{"title":"Corneal epithelial ingrowth after small incision lenticule extraction surgery: Insights from a case series and mechanistic studies","authors":"Miao Zhang,&nbsp;Ieng Chong,&nbsp;Xiaoniao Chen,&nbsp;Juan Yang,&nbsp;Linling Cheng,&nbsp;Zonghui Yan","doi":"10.1002/mef2.99","DOIUrl":"https://doi.org/10.1002/mef2.99","url":null,"abstract":"<p>Corneal epithelial ingrowth (EI) is a rare but significant complication following Small Incision Lenticule Extraction (SMILE) surgery. During the procedure, the opaque bubble layer (OBL) formation may create microchannels that disrupt Bowman's layer, providing a pathway for epithelial cells to migrate into the corneal stroma. In this study, we investigated the mechanisms behind EI development and proposed preventive strategies. We analyzed four cases of EI post-SMILE surgery, utilizing anterior segment optical coherence tomography (AS-OCT) and corneal tomography for diagnosis. Preventive measures, including careful anesthetic application and precise suction cone positioning, were employed to minimize OBL formation. Here, we show that subflap debris removal surgery led to significant clinical improvement, with no EI recurrence observed. Our findings suggest that the microchannels created by OBL during surgery may play a crucial role in EI development, challenging previous assumptions that EI is primarily due to trauma at the flap edges. This underscores the importance of precise surgical technique and effective postoperative management. Further research, including clinical studies and advanced imaging, is needed to confirm this proposed mechanism and improve outcomes in refractive surgery. The study highlights the necessity for ongoing advancements in surgical protocols and technology to prevent and manage EI effectively.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amplification editing: Achieving accurate replication of genome sequences from short fragments to chromosome length 扩增编辑:实现基因组序列从短片段到染色体长度的精确复制
Pub Date : 2024-09-04 DOI: 10.1002/mef2.95
Jianqiao Shentu, Yitao Zhao, Shiwei Duan
<p><i>Cell</i> recently published the breakthrough of amplification editing (AE) technology by Professor Hao Yin's team. This technology enables the amplification of short sequences to chromosome scale, achieving million-base amplification in both embryonic stem cells and primary cells. This opens up new avenues for precision medicine and genetic research.<span><sup>1</sup></span></p><p>In the biomedical field, the precise manipulation of the genome has long been a primary goal for scientists. From the debut of CRISPR-Cas9 to the sophisticated application of Prime Editing, each technological iteration represents a profound understanding and clever use of the laws of nature. However, although considerable progress has been made in gene editing technology, particularly in single-gene editing, challenges persist when addressing complex genomic structural variations. The current tools are mainly employed to modify specific gene sites, like point mutations or small insertions/deletions, but encounter numerous difficulties when dealing with large-scale structural variations such as gene amplification. The main issues encompass insufficient precision targeting ability, low efficiency, off-target effects, limited scope of application, and high technical complexity. Given that gene amplification plays a crucial role in genetic diseases and cancer, the inability to effectively identify and correct these variations will restrict the understanding of related disease mechanisms and impede the development of effective treatment strategies. Therefore, the development of precise and effective genome structural variation editing tools is an important direction for future research and treatment of complex genetic diseases.<span><sup>2</sup></span></p><p>Similar to twin prime editing (twinPE),<span><sup>3</sup></span> AE relies on a pair of prime editing guide RNAs (pegRNAs). The key difference is that in AE, the protospacer-adjacent motifs (PAMs) of the two pegRNAs are positioned on either side of the target site, whereas in twinPE, the PAM is inside the target site. This design allows for the generation of complementary 3′ protruding sequences on both sides of the target site. These sequences form a stable double-stranded DNA structure through annealing and binding, significantly improving sequence amplification and target site editing efficiency. The double-sided PAM design enhances pegRNA binding to the target site, increasing editing success rates. The complementary sequence increases the density of pegRNA binding sites, further improving accuracy and efficiency. Additionally, AE technology retains the complete pegRNA recognition site, making the editing product more stable, reducing synthesis errors, and facilitating subsequent processing and analysis (Figure 1).</p><p>The core innovation of AE technology lies in its ability to efficiently and accurately replicate DNA sequences from 20 bp to 100 Mb, while effectively avoiding nonspecific amplification and off
细胞》(Cell)杂志最近发表了尹浩教授团队突破性的扩增编辑(AE)技术。该技术可将短序列扩增到染色体尺度,在胚胎干细胞和原代细胞中实现百万碱基扩增,为精准医疗和基因研究开辟了新途径1。这为精准医学和基因研究开辟了新途径1。在生物医学领域,对基因组进行精确操作一直是科学家们的首要目标。从 CRISPR-Cas9 的首次亮相到 Prime Editing 的复杂应用,每一次技术迭代都代表着对自然规律的深刻理解和巧妙利用。然而,尽管基因编辑技术取得了长足的进步,尤其是在单基因编辑方面,但在处理复杂的基因组结构变异时,挑战依然存在。目前的工具主要用于修改特定的基因位点,如点突变或小的插入/缺失,但在处理基因扩增等大规模结构变异时却遇到了许多困难。主要问题包括精准靶向能力不足、效率低、脱靶效应、应用范围有限以及技术复杂性高。鉴于基因扩增在遗传病和癌症中起着至关重要的作用,如果不能有效识别和纠正这些变异,将限制对相关疾病机理的了解,阻碍有效治疗策略的开发。因此,开发精确有效的基因组结构变异编辑工具是未来研究和治疗复杂遗传疾病的重要方向。2 与孪生质粒编辑(twinPE)3 相似,AE 依靠一对质粒编辑向导 RNA(pegRNA)。其主要区别在于,在 AE 中,两个 pegRNA 的原位相邻基序(PAM)位于目标位点的两侧,而在 twinPE 中,PAM 位于目标位点的内部。这种设计可以在目标位点两侧产生互补的 3′ 突出序列。这些序列通过退火和结合形成稳定的双链 DNA 结构,大大提高了序列扩增和靶位点编辑效率。双面 PAM 设计增强了 pegRNA 与目标位点的结合,提高了编辑成功率。互补序列增加了 pegRNA 结合位点的密度,进一步提高了准确性和效率。此外,AE 技术保留了完整的 pegRNA 识别位点,使编辑产物更加稳定,减少了合成错误,便于后续处理和分析(图 1)。AE 技术的核心创新在于它能高效、准确地复制从 20 bp 到 100 Mb 的 DNA 序列,同时有效避免了传统基因编辑工具中常见的非特异性扩增和脱靶效应。与传统的 CRISPR-Cas9、TALENs 和 ZFNs 技术相比,AE 技术在扩增大规模 DNA 序列方面具有显著的效率和准确性。例如,CRISPR-Cas9 在扩增大规模 DNA 时可能会出现脱靶效应且效率较低,TALENs 和 ZFNs 技术受限于复杂的设计且效率不足,而传统的聚合酶链反应则可能对长 DNA 片段缺乏准确性。AE 技术通过优化 pegRNA 和 sgRNA 的设计克服了这些缺点,提供了一种更稳定、更高效的解决方案。在实际应用中,AE 技术的高效序列扩增和精确调控特性使其在干细胞和细胞生物学研究中大显身手。AE 技术可以上调非编码 RNA 和编码基因的表达,为基因表达调控提供了新工具。它还适用于构建复杂的染色体重复结构模型,以研究染色体结构变异对细胞功能和疾病的影响。例如,在模拟α-地中海贫血症的K562细胞模型中,AE技术用于扩增HBA1基因,证明了它在疾病建模方面的潜力。重要的是,AE 技术在疾病治疗方面前景广阔。它有望通过精确的序列扩增和修复,纠正癌症等遗传疾病的基因组缺陷,恢复正常的基因功能,从而为基因组编辑和个性化治疗提供新的可能。虽然 AE 技术已经取得了长足的进步,但它仍然面临着关键的挑战。AE 的编辑效率受到编辑片段长度的限制。例如,AE 对 1 Mb 片段的复制效率为 73%,而对 100 Mb 片段的复制效率则降至 1%-3.4%,编辑结果通常在 24 小时内难以检测到。
{"title":"Amplification editing: Achieving accurate replication of genome sequences from short fragments to chromosome length","authors":"Jianqiao Shentu,&nbsp;Yitao Zhao,&nbsp;Shiwei Duan","doi":"10.1002/mef2.95","DOIUrl":"https://doi.org/10.1002/mef2.95","url":null,"abstract":"&lt;p&gt;&lt;i&gt;Cell&lt;/i&gt; recently published the breakthrough of amplification editing (AE) technology by Professor Hao Yin's team. This technology enables the amplification of short sequences to chromosome scale, achieving million-base amplification in both embryonic stem cells and primary cells. This opens up new avenues for precision medicine and genetic research.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In the biomedical field, the precise manipulation of the genome has long been a primary goal for scientists. From the debut of CRISPR-Cas9 to the sophisticated application of Prime Editing, each technological iteration represents a profound understanding and clever use of the laws of nature. However, although considerable progress has been made in gene editing technology, particularly in single-gene editing, challenges persist when addressing complex genomic structural variations. The current tools are mainly employed to modify specific gene sites, like point mutations or small insertions/deletions, but encounter numerous difficulties when dealing with large-scale structural variations such as gene amplification. The main issues encompass insufficient precision targeting ability, low efficiency, off-target effects, limited scope of application, and high technical complexity. Given that gene amplification plays a crucial role in genetic diseases and cancer, the inability to effectively identify and correct these variations will restrict the understanding of related disease mechanisms and impede the development of effective treatment strategies. Therefore, the development of precise and effective genome structural variation editing tools is an important direction for future research and treatment of complex genetic diseases.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Similar to twin prime editing (twinPE),&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; AE relies on a pair of prime editing guide RNAs (pegRNAs). The key difference is that in AE, the protospacer-adjacent motifs (PAMs) of the two pegRNAs are positioned on either side of the target site, whereas in twinPE, the PAM is inside the target site. This design allows for the generation of complementary 3′ protruding sequences on both sides of the target site. These sequences form a stable double-stranded DNA structure through annealing and binding, significantly improving sequence amplification and target site editing efficiency. The double-sided PAM design enhances pegRNA binding to the target site, increasing editing success rates. The complementary sequence increases the density of pegRNA binding sites, further improving accuracy and efficiency. Additionally, AE technology retains the complete pegRNA recognition site, making the editing product more stable, reducing synthesis errors, and facilitating subsequent processing and analysis (Figure 1).&lt;/p&gt;&lt;p&gt;The core innovation of AE technology lies in its ability to efficiently and accurately replicate DNA sequences from 20 bp to 100 Mb, while effectively avoiding nonspecific amplification and off","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.95","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell-type-specific mRNA m6A landscape and regulatory mechanisms underlying pulmonary injury in COVID-19 细胞类型特异性 mRNA m6A 图谱和 COVID-19 肺损伤的调控机制
Pub Date : 2024-08-26 DOI: 10.1002/mef2.94
Peidong Zhang, Zhe Wang, Yuling Yang, Songqi Duan, Shengqian Dou, Huiying Sun, Chi Zhang, Xueying Li, Jinpeng Li, Yakun Liu, Mengmeng Sang, Xueqi Lv, Tianli Zhang, Chunxiao Chen, Fengcongzhe Gong, Xiaorui Ping, Wenlu Xing, Wenhao Ju, Yi Ping, Baofa Sun

Coronavirus disease 2019 (COVID-19) pandemic has caused millions of deaths. The risk of COVID-19 spreading still exists after the deconfinement act, Omicron became the dominant variant. Although N6-methyladenosine (m6A) regulators has been reported to affect the pathogenicity of COVID-19, their mechanism in the progression of lung injury in COVID-19 patients remain elusive. Here we show the landscape and specific mechanisms of m6A regulators in lung tissues through single-nucleus RNA sequencing (snRNA-Seq) data sets of 116,252 cells, and the external validation was performed using data from another snRNA-Seq data. The m6A reader IGF2BP2 was specifically upregulated in alveolar type I (AT1) cells, resulting in impaired lung regeneration. ALKBH5 expression upregulation in macrophages, impairing immune responses. Moreover, WTAP markedly upregulated in fibroblasts, leading to pulmonary fibrosis. In addition, m6A regulators dysregulation induced aberrant cell–cell communication in pulmonary tissue and mediated ligand–receptor interactions across diverse cell types in lung tissues by activating the TGF-β signaling pathway. Overall, these results indicated that the upregulation of m6A regulators in alveolar cells, myeloid cells, and fibroblasts may induce pulmonary injury in patients. The development of m6A-regulator inhibitors could be as one potential antifibrotic drugs for COVID-19.

冠状病毒病 2019(COVID-19)大流行已造成数百万人死亡。COVID-19的传播风险在去纤化法案之后仍然存在,奥米克龙成为了优势变种。尽管有报道称N6-甲基腺苷(m6A)调节因子会影响COVID-19的致病性,但它们在COVID-19患者肺损伤进展中的作用机制仍难以捉摸。在此,我们通过116252个细胞的单核RNA测序(snRNA-Seq)数据集展示了m6A调节因子在肺组织中的分布和特异性机制,并利用另一个snRNA-Seq数据进行了外部验证。m6A阅读器IGF2BP2在肺泡I型(AT1)细胞中特异性上调,导致肺再生功能受损。ALKBH5在巨噬细胞中表达上调,损害了免疫反应。此外,WTAP 在成纤维细胞中明显上调,导致肺纤维化。此外,m6A 调控因子失调会诱发肺组织细胞间的异常交流,并通过激活 TGF-β 信号通路,介导肺组织中不同类型细胞间的配体-受体相互作用。总之,这些结果表明,肺泡细胞、髓样细胞和成纤维细胞中 m6A 调节因子的上调可能会诱发患者的肺损伤。开发m6A调节剂抑制剂可作为COVID-19的一种潜在抗纤维化药物。
{"title":"Cell-type-specific mRNA m6A landscape and regulatory mechanisms underlying pulmonary injury in COVID-19","authors":"Peidong Zhang,&nbsp;Zhe Wang,&nbsp;Yuling Yang,&nbsp;Songqi Duan,&nbsp;Shengqian Dou,&nbsp;Huiying Sun,&nbsp;Chi Zhang,&nbsp;Xueying Li,&nbsp;Jinpeng Li,&nbsp;Yakun Liu,&nbsp;Mengmeng Sang,&nbsp;Xueqi Lv,&nbsp;Tianli Zhang,&nbsp;Chunxiao Chen,&nbsp;Fengcongzhe Gong,&nbsp;Xiaorui Ping,&nbsp;Wenlu Xing,&nbsp;Wenhao Ju,&nbsp;Yi Ping,&nbsp;Baofa Sun","doi":"10.1002/mef2.94","DOIUrl":"https://doi.org/10.1002/mef2.94","url":null,"abstract":"<p>Coronavirus disease 2019 (COVID-19) pandemic has caused millions of deaths. The risk of COVID-19 spreading still exists after the deconfinement act, Omicron became the dominant variant. Although N6-methyladenosine (m<sup>6</sup>A) regulators has been reported to affect the pathogenicity of COVID-19, their mechanism in the progression of lung injury in COVID-19 patients remain elusive. Here we show the landscape and specific mechanisms of m<sup>6</sup>A regulators in lung tissues through single-nucleus RNA sequencing (snRNA-Seq) data sets of 116,252 cells, and the external validation was performed using data from another snRNA-Seq data. The m<sup>6</sup>A reader <i>IGF2BP2</i> was specifically upregulated in alveolar type I (AT1) cells, resulting in impaired lung regeneration. <i>ALKBH5</i> expression upregulation in macrophages, impairing immune responses. Moreover, <i>WTAP</i> markedly upregulated in fibroblasts, leading to pulmonary fibrosis. In addition, m<sup>6</sup>A regulators dysregulation induced aberrant cell–cell communication in pulmonary tissue and mediated ligand–receptor interactions across diverse cell types in lung tissues by activating the TGF-β signaling pathway. Overall, these results indicated that the upregulation of m<sup>6</sup>A regulators in alveolar cells, myeloid cells, and fibroblasts may induce pulmonary injury in patients. The development of m<sup>6</sup>A-regulator inhibitors could be as one potential antifibrotic drugs for COVID-19.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.94","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142077995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensively dissecting onco-microbiome: Intriguing connection of the microbiome to cancer metastasis 全面剖析肿瘤微生物组:微生物组与癌症转移的惊人联系
Pub Date : 2024-08-04 DOI: 10.1002/mef2.93
Lan Yang, Hailin Zhang, Min Wu

In a recent paper published in Cell, Battaglia et al. provide a valuable pan-cancer analysis of the microbiome in metastatic cancer,1 which identified the specific preferences of microbes for different organs and demonstrated the correlations between diversity of microbes and neutrophils invasive into tumors, the anaerobic bacterial enrichments in hypoxic tumors, and the relationship between Fusobacterium and immune checkpoint blockade resistance in nonsmall cell lung cancer.

For over a century, researchers have observed the presence of bacteria in human tumors. However, the pathophysiological impact of intratumor microbiomes has been consistently ignored. Because of this overlook, despite our extensive knowledge of cancer and our array of treatment options, the microbiome has just been linked to cancer studies in the recent 20 years. Even though only a small number of bacteria are known to be directly carcinogenic, there has been a consistent rise in the number of bacteria that have an indirect impact on cancer.

The microbiome has been found to be linked to the tumor microenvironment, the initiation of innate immune sensing pathways, the tumor-infiltrating immune compartment, and the effectiveness of immunotherapy. The presence of microbes in local tissue, adjacent locations, and tumors themselves has been demonstrated to foster and inhibit the onset and growth of cancer. Moreover, these microbes have demonstrated the ability to influence the effectiveness of many cancer treatments, such as radiation, chemotherapy, and immunotherapy, which play a vital part in regulating the host immune system and influencing the body's response to anticancer treatments (Figure 1). Primary tumors contain intricate microbial communities, and current research indicates that certain types of cancer are significantly influenced by these microbes. In our view, it is crucial to comprehend the impact of the bacteria that exist in tumors on tumor biology, immunology, and therapeutic response. However, little is known about the existence and significance of the microbiome in relation to cancer, including the distinction in the microbial composition between the primary tumor and its metastases, the preferential colonization of bacteria in certain tumor types or organs, and the resilience of the microbial population during therapeutic interventions.

To this end, Battaglia et al. combined metagenomics, genomics, and transcriptomics techniques to examine the microbiota of metastatic tumors and their tumor-resident microbiome. They employed a bioinformatics methodology for data analysis, utilizing computational approaches such as Kraken2 and PathSeq, and also used high-throughput sequencing technology and various bioinformatics analysis approaches, including the STAR RNA-seq comparison tool and MutationalPatterns analysis, to enhance the precision and comprehensiveness of data processing and analysis. They analyzed 4164 samples of

研究发现,早期结直肠癌的多组学特征是富集黄杆菌,而晚期结直肠癌的多组学特征似乎与富集核酸镰刀菌有关。3 微生物衍生生物标志物有可能成为准确检测和区分早期结直肠癌患者的非侵入性工具,而且有利于加强患者分层。分析人类 RNA 测序数据可识别细菌信号并区分多种因素,如生存期、解剖位置、微卫星不稳定性、共识分子亚型和免疫细胞浸润。通过靶向吲哚-3-乳酸的核受体,服用核酸镰刀菌可下调白细胞介素 17 信号通路,从而抑制结直肠肿瘤的生长。总之,Battaglia 等人创建了首个全面的转移性肿瘤瘤内微生物组泛癌图谱,这被认为是一项值得关注的成就。他们利用新兴的高通量技术和生物信息学方法,最大限度地减少了样本或计算过程中产生的误差,为当前的肿瘤微生物组研究提供了创新性成果。要在这一领域取得进展,癌症生物学家和微生物学家之间必须开展合作。为了进一步研究微生物与癌症的分子机制,以及它们对肿瘤发生、肿瘤免疫、肿瘤转移和肿瘤治疗的影响,在大规模队列研究中采用高通量测序和单细胞测序等先进技术势在必行。在个性化医疗中应用免疫检查点阻断和免疫传感通路为未来的治疗方法带来了希望。综合研究、对各种肿瘤的分析以及建立强大的随访系统对于促进未来研究肿瘤内微生物组在癌症中复杂且潜在的可操控功能至关重要。杨澜撰写了手稿并绘制了图表。张海林和吴敏发起、指导并修改了手稿的撰写。所有作者均已阅读并批准最终稿件。作者声明无利益冲突。伦理声明不适用于本文。
{"title":"Comprehensively dissecting onco-microbiome: Intriguing connection of the microbiome to cancer metastasis","authors":"Lan Yang,&nbsp;Hailin Zhang,&nbsp;Min Wu","doi":"10.1002/mef2.93","DOIUrl":"https://doi.org/10.1002/mef2.93","url":null,"abstract":"<p>In a recent paper published in Cell, Battaglia et al. provide a valuable pan-cancer analysis of the microbiome in metastatic cancer,<span><sup>1</sup></span> which identified the specific preferences of microbes for different organs and demonstrated the correlations between diversity of microbes and neutrophils invasive into tumors, the anaerobic bacterial enrichments in hypoxic tumors, and the relationship between Fusobacterium and immune checkpoint blockade resistance in nonsmall cell lung cancer.</p><p>For over a century, researchers have observed the presence of bacteria in human tumors. However, the pathophysiological impact of intratumor microbiomes has been consistently ignored. Because of this overlook, despite our extensive knowledge of cancer and our array of treatment options, the microbiome has just been linked to cancer studies in the recent 20 years. Even though only a small number of bacteria are known to be directly carcinogenic, there has been a consistent rise in the number of bacteria that have an indirect impact on cancer.</p><p>The microbiome has been found to be linked to the tumor microenvironment, the initiation of innate immune sensing pathways, the tumor-infiltrating immune compartment, and the effectiveness of immunotherapy. The presence of microbes in local tissue, adjacent locations, and tumors themselves has been demonstrated to foster and inhibit the onset and growth of cancer. Moreover, these microbes have demonstrated the ability to influence the effectiveness of many cancer treatments, such as radiation, chemotherapy, and immunotherapy, which play a vital part in regulating the host immune system and influencing the body's response to anticancer treatments (Figure 1). Primary tumors contain intricate microbial communities, and current research indicates that certain types of cancer are significantly influenced by these microbes. In our view, it is crucial to comprehend the impact of the bacteria that exist in tumors on tumor biology, immunology, and therapeutic response. However, little is known about the existence and significance of the microbiome in relation to cancer, including the distinction in the microbial composition between the primary tumor and its metastases, the preferential colonization of bacteria in certain tumor types or organs, and the resilience of the microbial population during therapeutic interventions.</p><p>To this end, Battaglia et al. combined metagenomics, genomics, and transcriptomics techniques to examine the microbiota of metastatic tumors and their tumor-resident microbiome. They employed a bioinformatics methodology for data analysis, utilizing computational approaches such as Kraken2 and PathSeq, and also used high-throughput sequencing technology and various bioinformatics analysis approaches, including the STAR RNA-seq comparison tool and MutationalPatterns analysis, to enhance the precision and comprehensiveness of data processing and analysis. They analyzed 4164 samples of ","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.93","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141966475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of intestinal microbiota-derived metabolites on cancer and their potential application in tumor immunotherapy 肠道微生物群衍生代谢物对癌症的影响及其在肿瘤免疫疗法中的潜在应用
Pub Date : 2024-07-30 DOI: 10.1002/mef2.92
Mingyan Zhang, Feng Xie, Fangfang Zhou

In recent publications,1, 2 the group of Professor Zhu Shu/Pan Wen and the research team of Wang Liangjing/Chen Shujie, respectively investigated two intestinal microbial metabolites: deoxycholic acid (DCA) and indole-3-propionic acid (IPA). DCA acts on the calcium ion channel plasma membrane Ca2+ ATPase (PMCA), inhibits the effector function of CD8+ T cells and consequently promotes colorectal cancer (CRC) growth. IPA activates precursor-exhausted T (Tpex) cells and induces their transformation into effector T (Teff) cells, thereby increasing T-cell infiltration into the tumor tissue and enhancing the efficacy of immunotherapy (Figure 1).

Zhu et al. screened 73 small-molecule compounds derived from microbial sources to examine their effects on CD8+ T-cell-mediated cytotoxicity or IFN-γ production, and identified DCA. Subsequent experiments using sodium dodecyl sulfate (SDS) or other chemical inhibitors confirmed that DCA does not lead to cell death. In tumor immunity, CD8+ T cells are crucial in resisting tumors, with cytokines such as IFN-γ and TNF-α playing key roles in killing tumor cells. CD8+ T-cell activation relies on Ca2+ as a second messenger and the cytoplasmic Ca2+ concentration directly affects CD8+ T-cell activation. The authors found that DCA could inhibit cytoplasmic Ca2+ accumulation by monitoring the real-time fluorescence intensity of cytoplasmic Ca2+ in anti-CD3/CD28-activated CD8+ T cells.

NFAT2 is an important transcription factor regulating CD8+ T cells.3 According to immunoblotting results, DCA reduced the transcription of this factor. Using NFAT2-luciferase reporter gene assays, the authors observed that PMA/ionomycin stimulation increased the transcriptional activity of NFAT2. Notably, DCA supplementation attenuated this transcriptional activation, indicating that DCA could inhibit the NFAT2-mediated transcription induced by Ca2+ influx. To further study the specific effects of DCA, the authors examined several key observations. First, DCA did not reduce the levels of free calcium ions in cell-free culture medium, indicating that DCA does not chelate calcium ions. Second, the calcium-release activated channel (CRAC) was the main inward pathway. The immunosuppressive impact of DCA on CD8+ T cells persisted despite the presence of the selective CRAC channel blocker, BTP2, indicating that DCA did not affect calcium influx. Third, PMA/ionomycin induces Ca2+ to be released directly from the endoplasmic reticulum without relying on transporter proteins.1, 4 However, DCA inhibits Ca2+ accumulation, indicating that Ca2+ may flow out of the cell membrane in large quantities or into intracellular stores. Therefore, having blocked various ch

在最近发表的文章1、2中,朱曙/潘文教授课题组和王良静/陈淑杰研究团队分别研究了两种肠道微生物代谢产物:脱氧胆酸(DCA)和吲哚-3-丙酸(IPA)。DCA作用于钙离子通道质膜Ca2+ ATP酶(PMCA),抑制CD8+ T细胞的效应功能,从而促进结直肠癌(CRC)的生长。IPA能激活前体耗竭的T细胞(Tpex),并诱导它们转化为效应T细胞(Teff),从而增加T细胞对肿瘤组织的浸润,提高免疫疗法的疗效(图1)。随后使用十二烷基硫酸钠(SDS)或其他化学抑制剂进行的实验证实,DCA 不会导致细胞死亡。在肿瘤免疫中,CD8+ T 细胞是抵抗肿瘤的关键,IFN-γ 和 TNF-α 等细胞因子在杀死肿瘤细胞方面发挥着关键作用。CD8+ T细胞的活化依赖于作为第二信使的Ca2+,而细胞质中的Ca2+浓度会直接影响CD8+ T细胞的活化。作者通过监测抗 CD3/CD28 激活的 CD8+ T 细胞中胞质 Ca2+ 的实时荧光强度发现,DCA 可抑制胞质 Ca2+ 的积累。3 根据免疫印迹结果,DCA 降低了该因子的转录。作者使用 NFAT2luciferase 报告基因检测法观察到,PMA/洋霉素刺激增加了 NFAT2 的转录活性。值得注意的是,补充 DCA 可减轻这种转录激活,表明 DCA 可抑制 Ca2+ 流入诱导的 NFAT2 介导的转录。为了进一步研究 DCA 的具体作用,作者研究了几个关键的观察结果。首先,DCA 不会降低无细胞培养基中游离钙离子的水平,这表明 DCA 不会螯合钙离子。其次,钙释放激活通道(CRAC)是主要的内向途径。尽管存在选择性 CRAC 通道阻断剂 BTP2,但 DCA 对 CD8+ T 细胞的免疫抑制作用依然存在,这表明 DCA 并不影响钙离子的流入。第三,PMA/阴离子霉素可诱导 Ca2+ 直接从内质网释放,而不依赖于转运蛋白。因此,在阻断了各种已知可抑制细胞质 Ca2+ 水平的通道后,作者发现 DCA 可通过增强 PMCA 介导的 Ca2+ 外流来抑制细胞质 Ca2+ 的积累,并使用 PMCA 抑制剂验证了这一点。然而,有关 DCA 与 PMCA 精确结合位点的研究仍然有限。作者根据 DCA 的机制提出了一种可能的治疗策略。他们从城市污水中分离出一种噬菌体,这种噬菌体的目标是裂解 C. scindens。这种噬菌体能有效降低血清中的 DCA 浓度,缓解肿瘤生长,增强 CD8+ T 细胞的效应功能,从而为 CRC 提供了一条潜在的治疗途径。1 此外,在之前的实验中,使用抑制剂 LaCl3 或干扰 shPMCA 可抑制 PMCA,同样缓解了对 CD8+ T 细胞的抑制。PMCA抑制剂可作为一种辅助疗法,用于那些DCA分泌细菌较多的患者。Zhu等人的研究强调,增强CD8+ T细胞活性是免疫疗法策略的一个关键方面。Wang 等人发现,IPA 能增强 CD8+ T 细胞的活性。他们对IPA提高肿瘤对免疫检查点阻断(ICB)反应性的机制进行了深入研究。Wang等人根据αPD-1疗法将小鼠分为反应差组和反应好组,分析了微生物群落的差异。在物种水平上,约翰逊乳杆菌的差异最大。这与人类 CRC 组织中的发现一致,在人类 CRC 组织中,这种细菌的丰度与肿瘤进展呈负相关。为了进一步研究特定物质的影响,作者将小鼠分组,用含有各种细菌的不同培养基进行处理。结果显示,只有约翰逊酵母调节培养基(Lj.CM)对肿瘤有良好的治疗效果,与直接口服约翰逊酵母的效果相当。
{"title":"The impact of intestinal microbiota-derived metabolites on cancer and their potential application in tumor immunotherapy","authors":"Mingyan Zhang,&nbsp;Feng Xie,&nbsp;Fangfang Zhou","doi":"10.1002/mef2.92","DOIUrl":"https://doi.org/10.1002/mef2.92","url":null,"abstract":"<p>In recent publications,<span><sup>1, 2</sup></span> the group of Professor Zhu Shu/Pan Wen and the research team of Wang Liangjing/Chen Shujie, respectively investigated two intestinal microbial metabolites: deoxycholic acid (DCA) and indole-3-propionic acid (IPA). DCA acts on the calcium ion channel plasma membrane Ca<sup>2+</sup> ATPase (PMCA), inhibits the effector function of CD8<sup>+</sup> T cells and consequently promotes colorectal cancer (CRC) growth. IPA activates precursor-exhausted T (T<sub>pex</sub>) cells and induces their transformation into effector T (T<sub>eff</sub>) cells, thereby increasing T-cell infiltration into the tumor tissue and enhancing the efficacy of immunotherapy (Figure 1).</p><p>Zhu et al. screened 73 small-molecule compounds derived from microbial sources to examine their effects on CD8<sup>+</sup> T-cell-mediated cytotoxicity or IFN-γ production, and identified DCA. Subsequent experiments using sodium dodecyl sulfate (SDS) or other chemical inhibitors confirmed that DCA does not lead to cell death. In tumor immunity, CD8<sup>+</sup> T cells are crucial in resisting tumors, with cytokines such as IFN-γ and TNF-α playing key roles in killing tumor cells. CD8<sup>+</sup> T-cell activation relies on Ca<sup>2+</sup> as a second messenger and the cytoplasmic Ca<sup>2+</sup> concentration directly affects CD8<sup>+</sup> T-cell activation. The authors found that DCA could inhibit cytoplasmic Ca<sup>2+</sup> accumulation by monitoring the real-time fluorescence intensity of cytoplasmic Ca<sup>2+</sup> in anti-CD3/CD28-activated CD8<sup>+</sup> T cells.</p><p>NFAT2 is an important transcription factor regulating CD8<sup>+</sup> T cells.<span><sup>3</sup></span> According to immunoblotting results, DCA reduced the transcription of this factor. Using NFAT2-luciferase reporter gene assays, the authors observed that PMA/ionomycin stimulation increased the transcriptional activity of NFAT2. Notably, DCA supplementation attenuated this transcriptional activation, indicating that DCA could inhibit the NFAT2-mediated transcription induced by Ca<sup>2+</sup> influx. To further study the specific effects of DCA, the authors examined several key observations. First, DCA did not reduce the levels of free calcium ions in cell-free culture medium, indicating that DCA does not chelate calcium ions. Second, the calcium-release activated channel (CRAC) was the main inward pathway. The immunosuppressive impact of DCA on CD8<sup>+</sup> T cells persisted despite the presence of the selective CRAC channel blocker, BTP2, indicating that DCA did not affect calcium influx. Third, PMA/ionomycin induces Ca<sup>2+</sup> to be released directly from the endoplasmic reticulum without relying on transporter proteins.<span><sup>1, 4</sup></span> However, DCA inhibits Ca<sup>2+</sup> accumulation, indicating that Ca<sup>2+</sup> may flow out of the cell membrane in large quantities or into intracellular stores. Therefore, having blocked various ch","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.92","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141968362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cordyceps sinensis ameliorates idiopathic pulmonary fibrosis in mice via inhibiting mitochondrion-mediated oxidative stress 冬虫夏草通过抑制线粒体介导的氧化应激改善小鼠的特发性肺纤维化
Pub Date : 2024-07-19 DOI: 10.1002/mef2.91
Ying Zhang, Lirun Zhou, Guangqing Cheng, Yanyan Zhou, Qiuyan Guo, Jiangpeng Wu, Yin K. Wong, Junzhe Zhang, Huan Tang, Jigang Wang

Idiopathic pulmonary fibrosis (IPF) represents a chronic interstitial lung disease with an unclear underlying mechanism and currently lacks a definitive treatment. Cordyceps sinensis (CS), renowned for its pharmacological properties in traditional Chinese medicine and extensive use in lung disease treatment, holds promise as a therapeutic agent for IPF. However, the specific role of CS in treating IPF remains unclear. In this study, we aimed to assess the efficacy of CS in treating IPF and unravel potential underlying mechanisms. Our results demonstrate that CS treatment effectively mitigated pulmonary inflammation and collagen deposition in bleomycin-induced IPF mice. Proteomics analysis revealed that the regulation of mitochondrial oxidative phosphorylation may serve as a potential protective mechanism of CS against IPF in mice. Further investigation unveiled that CS could suppress the excessive production of mitochondrial reactive oxygen species in lung tissues induced by bleomycin through moderating the expression and activity of mitochondrial complexes, thus safeguarding the integrity and function of mitochondria. Overall, our findings not only underscore the effectiveness of CS in preventing bleomycin-induced IPF but also highlight mitochondrial-mediated oxidative stress as a promising therapeutic target for treating IPF.

特发性肺纤维化(IPF)是一种慢性间质性肺病,其发病机制尚不清楚,目前缺乏明确的治疗方法。冬虫夏草(Cordyceps sinensis,CS)因其在传统中药中的药理特性而闻名,并被广泛用于肺部疾病的治疗,有望成为治疗 IPF 的药物。然而,CS 在治疗 IPF 中的具体作用仍不清楚。在本研究中,我们旨在评估 CS 治疗 IPF 的疗效,并揭示其潜在的内在机制。我们的研究结果表明,CS 能有效缓解博莱霉素诱导的 IPF 小鼠的肺部炎症和胶原沉积。蛋白质组学分析表明,线粒体氧化磷酸化的调节可能是 CS 对小鼠 IPF 的潜在保护机制。进一步研究发现,CS 可以通过调节线粒体复合物的表达和活性,抑制博莱霉素诱导的肺组织中线粒体活性氧的过度产生,从而保护线粒体的完整性和功能。总之,我们的研究结果不仅强调了CS在预防博莱霉素诱导的IPF方面的有效性,还强调了线粒体介导的氧化应激是治疗IPF的一个很有前景的治疗靶点。
{"title":"Cordyceps sinensis ameliorates idiopathic pulmonary fibrosis in mice via inhibiting mitochondrion-mediated oxidative stress","authors":"Ying Zhang,&nbsp;Lirun Zhou,&nbsp;Guangqing Cheng,&nbsp;Yanyan Zhou,&nbsp;Qiuyan Guo,&nbsp;Jiangpeng Wu,&nbsp;Yin K. Wong,&nbsp;Junzhe Zhang,&nbsp;Huan Tang,&nbsp;Jigang Wang","doi":"10.1002/mef2.91","DOIUrl":"https://doi.org/10.1002/mef2.91","url":null,"abstract":"<p>Idiopathic pulmonary fibrosis (IPF) represents a chronic interstitial lung disease with an unclear underlying mechanism and currently lacks a definitive treatment. <i>Cordyceps sinensis</i> (CS), renowned for its pharmacological properties in traditional Chinese medicine and extensive use in lung disease treatment, holds promise as a therapeutic agent for IPF. However, the specific role of CS in treating IPF remains unclear. In this study, we aimed to assess the efficacy of CS in treating IPF and unravel potential underlying mechanisms. Our results demonstrate that CS treatment effectively mitigated pulmonary inflammation and collagen deposition in bleomycin-induced IPF mice. Proteomics analysis revealed that the regulation of mitochondrial oxidative phosphorylation may serve as a potential protective mechanism of CS against IPF in mice. Further investigation unveiled that CS could suppress the excessive production of mitochondrial reactive oxygen species in lung tissues induced by bleomycin through moderating the expression and activity of mitochondrial complexes, thus safeguarding the integrity and function of mitochondria. Overall, our findings not only underscore the effectiveness of CS in preventing bleomycin-induced IPF but also highlight mitochondrial-mediated oxidative stress as a promising therapeutic target for treating IPF.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.91","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141732553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the influence of metabolic signatures on immune dynamics for predicting immunotherapy response and survival in cancer 揭示代谢特征对免疫动态的影响,预测癌症的免疫疗法反应和存活率
Pub Date : 2024-06-25 DOI: 10.1002/mef2.89
Qiyun Ou, Zhiqiang Lu, Gengyi Cai, Zijia Lai, Ruicong Lin, Hong Huang, Dongqiang Zeng, Zehua Wang, Baoming Luo, Wenhao Ouyang, Wangjun Liao

Metabolic reprogramming in cancer significantly impacts immune responses within the tumor microenvironment, but its influence on cancer immunotherapy effectiveness remains uncertain. This study aims to elucidate the prognostic significance of metabolic genes in cancer immunotherapy through a comprehensive analytical approach. Utilizing data from the IMvigor210 trial (n = 348) and validated by retrospective datasets, we performed patient clustering using non-negative matrix factorization based on metabolism-related genes. A metabiotic score was developed using a “DeepSurv” neural network to assess correlations with overall survival (OS), progression-free survival, and immunotherapy response. Validation of the metabolic score and key genes was achieved via comparative gene expression analysis using qPCR. Our analysis identified four distinct metabolic classes with significant variations in OS. Notably, the metabolism-inactive and hypoxia-low class demonstrated the most pronounced benefit in terms of OS. The metabolic score predicted immunotherapeutic benefits with high accuracy (AUC: 0.93 at 12 months). SETD3 emerged as a crucial gene, showing strong correlations with improved OS outcomes. This study underscores the importance of metabolic profiling in predicting cancer immunotherapy success. Specifically, patients classified as metabolism-inactive and hypoxia-low appear to derive substantial benefits. SETD3 is established as a promising prognostic marker, linking metabolic activity with patient outcomes, advocating for the integration of metabolic profiling into immunotherapy strategies to enhance treatment precision and efficacy.

癌症中的代谢重编程会显著影响肿瘤微环境中的免疫反应,但其对癌症免疫治疗效果的影响仍不确定。本研究旨在通过综合分析方法阐明代谢基因在癌症免疫疗法中的预后意义。利用 IMvigor210 试验(n = 348)的数据,并通过回顾性数据集进行验证,我们使用基于代谢相关基因的非负矩阵因式分解法对患者进行了聚类。使用 "DeepSurv "神经网络开发了代谢评分,以评估与总生存期(OS)、无进展生存期和免疫疗法反应的相关性。通过使用 qPCR 进行比较基因表达分析,对代谢评分和关键基因进行了验证。我们的分析确定了四种不同的代谢类别,它们在OS方面存在显著差异。值得注意的是,新陈代谢不活跃和低缺氧类在OS方面表现出最明显的获益。代谢评分预测免疫治疗获益的准确度很高(12个月时的AUC:0.93)。SETD3是一个关键基因,与改善的OS结果显示出很强的相关性。这项研究强调了代谢分析在预测癌症免疫疗法成功方面的重要性。具体来说,被归类为代谢不活跃和低氧血症的患者似乎能从中获益良多。SETD3是一个很有前景的预后标志物,它将代谢活性与患者的预后联系在一起,主张将代谢谱分析纳入免疫疗法策略,以提高治疗的精确性和疗效。
{"title":"Unraveling the influence of metabolic signatures on immune dynamics for predicting immunotherapy response and survival in cancer","authors":"Qiyun Ou,&nbsp;Zhiqiang Lu,&nbsp;Gengyi Cai,&nbsp;Zijia Lai,&nbsp;Ruicong Lin,&nbsp;Hong Huang,&nbsp;Dongqiang Zeng,&nbsp;Zehua Wang,&nbsp;Baoming Luo,&nbsp;Wenhao Ouyang,&nbsp;Wangjun Liao","doi":"10.1002/mef2.89","DOIUrl":"https://doi.org/10.1002/mef2.89","url":null,"abstract":"<p>Metabolic reprogramming in cancer significantly impacts immune responses within the tumor microenvironment, but its influence on cancer immunotherapy effectiveness remains uncertain. This study aims to elucidate the prognostic significance of metabolic genes in cancer immunotherapy through a comprehensive analytical approach. Utilizing data from the IMvigor210 trial (<i>n</i> = 348) and validated by retrospective datasets, we performed patient clustering using non-negative matrix factorization based on metabolism-related genes. A metabiotic score was developed using a “DeepSurv” neural network to assess correlations with overall survival (OS), progression-free survival, and immunotherapy response. Validation of the metabolic score and key genes was achieved via comparative gene expression analysis using qPCR. Our analysis identified four distinct metabolic classes with significant variations in OS. Notably, the metabolism-inactive and hypoxia-low class demonstrated the most pronounced benefit in terms of OS. The metabolic score predicted immunotherapeutic benefits with high accuracy (AUC: 0.93 at 12 months). SETD3 emerged as a crucial gene, showing strong correlations with improved OS outcomes. This study underscores the importance of metabolic profiling in predicting cancer immunotherapy success. Specifically, patients classified as metabolism-inactive and hypoxia-low appear to derive substantial benefits. SETD3 is established as a promising prognostic marker, linking metabolic activity with patient outcomes, advocating for the integration of metabolic profiling into immunotherapy strategies to enhance treatment precision and efficacy.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.89","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141488825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lessons from COVID-19: Aspects of prevention, therapeutics, and diagnostics against SARS-CoV-2 with special focus on JN.1 and XBB sublineages COVID-19 的经验教训:预防、治疗和诊断 SARS-CoV-2 的各个方面,特别关注 JN.1 和 XBB 亚系
Pub Date : 2024-06-19 DOI: 10.1002/mef2.90
Puja Jaishwal, Upagya Gyaneshwari, Kisalay Jha, Brijesh Pandey, Thakur P. Yadav, Satarudra P. Singh

The end of second decade in the 21st century witnessed a prominent disease outbreak caused by the novel coronavirus SARS-CoV-2 (including most diverse omicron subvariants), where the death toll crossed the boundary of 6.9 million across the globe by December 19, 2023. All spheres of central dogma of molecular biology and host‒pathogen interaction was explored to find ways in diagnostics, isolation, curtailment, and therapy. Above all, diagnostics and therapeutics against COVID-19 took an enormous jump, which needs to be evaluated for accuracy and feasibility and requires serious compilation for current and future generations. With the same objective, this review encompasses the diverse ways including prevention practiced and proposed during the handling of this pandemic across the globe. It involves the role of mutations in viruses and subsequent epitope mapping with potential immune escape mechanisms of SARS-CoV-2 variants including the conservancy of T-cell epitopes has also been highlighted. The efficacy in antigen/antibody-based diagnostics, RT‒PCR- and NGS-based confirmation of pathogen presence, and imaging (X-ray/CT-scan) for symptoms and damage assessment has been thoroughly filtered. The possibility of errors in diagnostics and their cause and consequences have also been presented for the ease of readers and further improvisers.

21 世纪第二个十年末期,新型冠状病毒 SARS-CoV-2(包括最多样的奥米克亚变种)引发了一场严重的疾病爆发,到 2023 年 12 月 19 日,全球死亡人数已超过 690 万。人们探索了分子生物学和宿主-病原体相互作用的所有核心原理,以找到诊断、分离、遏制和治疗的方法。最重要的是,针对 COVID-19 的诊断和治疗方法有了巨大的飞跃,需要对其准确性和可行性进行评估,并需要为当代和后代进行认真的编纂。出于同样的目的,这篇综述涵盖了在全球范围内处理这一流行病时所采用和提出的各种方法,包括预防方法。它涉及病毒变异的作用以及随后的表位图谱和 SARS-CoV-2 变体的潜在免疫逃逸机制,包括 T 细胞表位的保留。对基于抗原/抗体的诊断、基于 RT-PCR 和 NGS 的病原体存在确认以及用于症状和损害评估的成像(X 光/CT 扫描)的有效性进行了彻底筛选。此外,还介绍了诊断中可能出现的错误及其原因和后果,以方便读者和进一步改进者。
{"title":"Lessons from COVID-19: Aspects of prevention, therapeutics, and diagnostics against SARS-CoV-2 with special focus on JN.1 and XBB sublineages","authors":"Puja Jaishwal,&nbsp;Upagya Gyaneshwari,&nbsp;Kisalay Jha,&nbsp;Brijesh Pandey,&nbsp;Thakur P. Yadav,&nbsp;Satarudra P. Singh","doi":"10.1002/mef2.90","DOIUrl":"https://doi.org/10.1002/mef2.90","url":null,"abstract":"<p>The end of second decade in the 21st century witnessed a prominent disease outbreak caused by the novel coronavirus SARS-CoV-2 (including most diverse omicron subvariants), where the death toll crossed the boundary of 6.9 million across the globe by December 19, 2023. All spheres of central dogma of molecular biology and host‒pathogen interaction was explored to find ways in diagnostics, isolation, curtailment, and therapy. Above all, diagnostics and therapeutics against COVID-19 took an enormous jump, which needs to be evaluated for accuracy and feasibility and requires serious compilation for current and future generations. With the same objective, this review encompasses the diverse ways including prevention practiced and proposed during the handling of this pandemic across the globe. It involves the role of mutations in viruses and subsequent epitope mapping with potential immune escape mechanisms of SARS-CoV-2 variants including the conservancy of T-cell epitopes has also been highlighted. The efficacy in antigen/antibody-based diagnostics, RT‒PCR- and NGS-based confirmation of pathogen presence, and imaging (X-ray/CT-scan) for symptoms and damage assessment has been thoroughly filtered. The possibility of errors in diagnostics and their cause and consequences have also been presented for the ease of readers and further improvisers.</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"3 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.90","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
MedComm - Future medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1